18th week of 2020 patent applcation highlights part 26 |
Patent application number | Title | Published |
20200131231 | CELL PENETRATING PEPTIDES - The present invention relates to peptides, in particular cell penetrating peptides, of 40 amino acid residues or less comprising at least one directly glycosylated amino residue and one or more arginine rich arm domains, and to conjugates of such cell penetrating peptides with a therapeutic molecule. The present invention further relates to the use of the peptides or conjugates in methods of treatment or as a medicament, especially in the treatment of genetic disorders of the central nervous system. page. | 2020-04-30 |
20200131232 | CRYSTAL STRUCTURE OF THE LARGE RIBOSOMAL SUBUNIT FROM S. AUREUS - A composition-of-matter comprising a crystallized form of a large ribosomal (50S) subunit of a pathogenic bacterium, and the atomic coordinates of the three-dimensional structure thereof are provided herein, as well as methods for crystallizing the same, and using the atomic coordinates of the same to design de novo ligands with high specificity thereto. | 2020-04-30 |
20200131233 | PROTEINS AND PEPTIDE TAGS WITH ENHANCED RATE OF SPONTANEOUS ISOPEPTIDE BOND FORMATION AND USES THEREOF - The present invention relates to a two-part linker comprising a peptide tag (peptide) and a polypeptide (protein) that is capable of spontaneously forming an isopeptide bond, particularly wherein: a) said peptide comprises an amino acid sequence as set forth in SEQ ID NO: 1, wherein: (i) X at position 1 is arginine or no amino acid; (ii) X at position 2 is glycine or no amino acid; (iii) X at position 5 is histidine or threonine; (iv) X at position 11 is alanine, glycine or valine; and (v) X at position 14 is arginine or lysine, wherein when X at position 1 is no amino acid, X at position 2 is no amino acid; and b) said polypeptide comprises: i) an amino acid sequence as set forth in SEQ ID NO: 2; ii) a portion of (i) comprising an amino acid sequence as set forth in SEQ ID NO: 101; iii) an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 2, wherein said amino acid sequence comprises a lysine at position 34, a glutamic acid at position 80 and one or more of the following: 1) threonine at position 5; 2) proline at position 16; 3) arginine at position 40; 4) histidine at position 65; 5) proline at position 92; 6) aspartic acid at position 100: 7) glutamic acid at position 108; and 8) threonine at position 116, wherein the specified amino acid residues are at positions equivalent to the positions in SEQ ID NO: 2; or iv) a portion of (iii) comprising an amino acid sequence with at least 80% sequence identity to a sequence as set forth in SEQ ID NO: 101, wherein the amino acid sequence comprises a lysine at position 10, a glutamic acid at position 56 and one or more of the following: 1) arginine at position 16; 2) histidine at position 41; 3) proline at position 68; and 4) aspartic acid at position 76, wherein the specified amino acid residues are at positions equivalent to the positions in SEQ ID NO: 101, and wherein said peptide and polypeptide are capable of spontaneously forming an isopeptide bond between the aspartic acid residue at position 10 of SEQ ID NO: 1 and the lysine residue at position 34 of SEQ ID NO: 2 or position 10 of SEQ ID NO: 101. | 2020-04-30 |
20200131234 | MICROPEPTIDES AND USE OF SAME FOR MODULATING GENE EXPRESSION - Process for detecting and identifying micropeptides (miPEPs) encoded by a nucleotide sequence contained in the sequence of the primary transcript of a microRNA and use thereof for modulating gene expression. | 2020-04-30 |
20200131235 | RECOMBINANT DERMATOPHAGOIDES PTERONYSSINUS TYPE 2 ALLERGEN PROTEIN AND ITS PREPARATION METHOD AND APPLICATION - Provided are a recombinant group 2 allergen protein from | 2020-04-30 |
20200131236 | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS - Nonsense-mediated mRNA decay (NMD) polypeptides, nucleic acids encoding NMD polypeptides, and methods of using such polypeptides and nucleic acids in the treatment of ALS and in screening for agents for the treatment of ALS are described. | 2020-04-30 |
20200131237 | TREATMENT OF NERVOUS SYSTEM INJURY AND NEURODEGENERATIVE DISORDERS AND RELATED CONDITIONS - Provided herein are compositions, systems, kits, and methods for treating nervous system injuries caused by trauma or neurodegeneration or aging in a subject by administering a CSPG or SOCS3 reduction peptide (CRP and SRP respectively), or a nucleic acid sequence encoding the CRP or SRP, wherein both the CRP and SRP comprise a cell membrane penetrating domain, and a lysosome targeting domain, and the CRP further comprises a chondroitin sulfate proteoglycan (CSPG) binding domain, and the SRP further comprises a suppressor of cytokine signaling-3 (SOCS3) binding domain. | 2020-04-30 |
20200131238 | METHOD FOR PROMOTING ADIPOCYTE DIFFERENTIATION AND OBESITY-RELATED DISEASE TREATMENT - Here we show that epigenetic control of Neuregulin-1 (NRG1) affects adipose differentiation of stem cells in vitro. Building on this finding, we established a model in which NRG1 is a white adipose tissue (WAT) specific regulator analogous to the role of NRG4 in black adipose tissue (BAT). In this light, NRG1 functions in a paracrine or autocrine manner to regulate formation of new adipocytes from stem populations, both in vitro and in vivo. In neurons, NRG1 has been shown already to play a similar role, promoting neuronal cell differentiation from progenitors in the vertebrate cortex and retina and even promoting neuronal differentiation in vitro. Similarly, in the heart, NRG1 promotes differentiation of cardiomyocytes from their stem cell progenitors both in vivo and in vitro and for this reason has been successfully tested in clinical trials for heart failure. Our model extends these findings to adipose biology and indicates that epigenetic control of NRG1 may constitute an intrinsic mechanism limiting the expansion of WAT depots, potentially elucidating important health implications for the comorbidities of obesity and providing treatment for obesity-related diseases. | 2020-04-30 |
20200131239 | Methods and Compositions for Promoting Immune Cell Function - The present disclosure features, at least in part, methods for conserving cell function, e.g., immune cell function, e.g., after one or more cycles of freezing and/or thawing the nucleated cell. In embodiments, the methods comprise contacting an immune cell with a protein nanoparticle comprising an IL-15 complex. | 2020-04-30 |
20200131240 | USE OF IL-12 TO GENERATE ENDOGENOUS ERYTHROPOIETIN - The present invention relates to the use of exogenous interleukin-12 (IL-12) for increasing endogenous production of erythropoietin. | 2020-04-30 |
20200131241 | Type I Interferon Signatures and Methods of Use - Type I interferon (IFN-I) signatures are useful in methods of diagnosing whether a subject (or patient) with IFN-I mediated disease will be responsive to treatment with an IFN-I inhibitor and treating or refraining from treating the subjects. | 2020-04-30 |
20200131242 | METHODS OF TREATMENT WITH LONG-ACTING HORMONE - Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing weight loss or body fat reduction, methods of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed. | 2020-04-30 |
20200131243 | INSULIN-FC FUSIONS AND METHODS OF USE - The present disclosure relates generally to compositions of insulin-Fc (e.g., proinsulin-Fc) fusion proteins and their use to treat autoimmune disease, e.g., autoimmune diabetes, e.g., Type 1 diabetes. | 2020-04-30 |
20200131244 | Truncated NKG2D Chimeric Receptors And Uses Thereof In Natural Killer Cell Immunotherapy - Several embodiments disclosed herein relate to the compositions comprising engineered Natural Killer (NK) cells that express a chimeric receptor, the chimeric receptor imparting to the NK cells an enhanced ability to target specific cells, such as cancerous cells or those affected by an infectious disease. Several embodiments relate to NK cells that target cells expressing natural ligands of NKG2D, where the NK cells comprise transmembrane and/or signaling domains that lead to cytotoxic and/or cytolytic effects when the NK cells bind a target cell. Uses of NK cell compositions to treat diseases are also provided for in several embodiments. | 2020-04-30 |
20200131245 | TREATING INFLAMMATION WITH SOLUBLE HYBRID FCGAMMA RECEPTORS - Disclosed are soluble hybrid Fcγ receptor (FcγR) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid FcγR polypeptides. | 2020-04-30 |
20200131246 | VEGF ANTAGONIST FORMULATIONS SUITABLE FOR INTRAVITREAL ADMINISTRATION - Ophthalmic formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided suitable for intravitreal administration to the eye. The ophthalmic formulations include a stable liquid formulation and a lyophilizable formulation. Preferably, the protein antagonist has an amino acid sequence of SEQ ID NO:4. | 2020-04-30 |
20200131247 | MODIFIED HAEMOGLOBIN PROTEINS - The present invention relates to modified proteins e.g. oxygen-carrying proteins, with improved or enhanced, in comparison to a reference protein, reduction of a metal ion associated with the modified protein. The present invention also relates to methods of using such modified proteins and compositions comprising such proteins e.g. in therapy. | 2020-04-30 |
20200131248 | THERAPY USING A FACTOR XII INHIBITOR IN A NEUROTRAUMATIC DISORDER - The present invention relates to the use of a direct Factor XII (FXII) inhibitor in the treatment of a neurotraumatic disorder resulting from a traumatic injury of the brain (traumatic brain injury, TBI) or the spinal cord (spinal cord injury, SCI). | 2020-04-30 |
20200131249 | NOVEL PROTEINS AND USE THEREOF - The invention relates to proteins containing any of the sequences according to general formula (Ih): | 2020-04-30 |
20200131250 | METHOD FOR MEASURING VISCOSITY OF PROTEIN SOLUTION - The inventors discovered that viscosity of a protein solution can be estimated by measuring the apparent particle size or apparent molecular weight by a small angle X-ray scattering (SAXS) method or X-ray solution scattering method, which enables measurement of small amounts of samples, and then correlating those measurement results with viscosity of the protein solution. | 2020-04-30 |
20200131251 | IMPROVED METHODS FOR ENHANCING ANTIBODY PRODUCTIVITY IN MAMMALIAN CELL CULTURE AND MINIMIZING AGGREGATION DURING DOWNSTREAM, FORMULATION PROCESSES AND STABLE ANTIBODY FORMULATIONS OBTAINED THEREOF - The invention describes an efficient platform for antibody manufacturing and formulation that provides i) cell culture process with improved feeding strategy resulting in high antibody titer between 2 gm/L to 5 gm/L; ii) improved purification process showing optimal percentage recovery, high purity monomer content, minimum aggregation/particulate formation, minimum impurity levels; and iii) high concentration stable liquid formulation with optimal osmolality and low viscosity across different temperature excursions and devoid of aggregation. The preferred antibodies include IgG1 monoclonal antibody specific to the Dengue virus epitope in domain III of the E protein and IgG1 monoclonal antibody specific to the rabies virus surface G glycoprotein. | 2020-04-30 |
20200131252 | Compositions and methods for treating and preventing staphylococcus aureus infections - Antibodies having Fab regions that specifically bind to | 2020-04-30 |
20200131253 | MODULATION OF COMPLEMENT-DEPENDENT CYTOTOXICITY THROUGH MODIFICATIONS OF THE C-TERMINUS OF ANTIBODY HEAVY CHAINS - Antibody variants having decreased or increased ability to mediate CDC due to modifications at the C-terminus of their heavy chains are described. Methods of generating such antibodies, as well as nucleotide constructs and host cells suitable for the production of said antibodies are also described. | 2020-04-30 |
20200131254 | Analysis of Ubiquitinated Polypeptides - The disclosure relates to antibody reagents that specifically bind to peptides carrying a ubiquitin remnant from a digested or chemically treated biological sample. The reagents allow the technician to identify ubiquitinated polypeptides as well as the sites of ubiquitination on them. The reagents are preferably employed in proteomic analysis using mass spectrometry. The antibody reagents specifically bind to the remnant of ubiquitin (i.e., a diglycine modified epsilon amine of lysine) left on a peptide which as been generated by digesting or chemically treating ubiquitinated proteins. The inventive antibody reagents' affinity to the ubiquitin remnant does not depend on the remaining amino acid sequences flanking the modified (i.e., ubiquitinated) lysine, i.e., they are context independent. | 2020-04-30 |
20200131255 | METHODS OF TREATING NEURODEGENERATIVE DISEASES - The invention provides methods of treating tauopathies with anti-Tau antibodies. | 2020-04-30 |
20200131256 | ANTI-PACAP ANTIBODY - Antibodies to human pituitary adenylate cyclase-activating peptide, compositions comprising such antibodies, and methods of using such antibodies for the treatment of pain including headache and/or migraine. | 2020-04-30 |
20200131257 | Compositions and Methods For Treating or Preventing Endocrine FGF-Linked Diseases - The present invention relates in one aspect to the discovery that β-Klotho is the primary cell-surface receptor for FGF21, with FGFR1c functioning as a catalytic subunit that ultimately mediates intracellular signaling. In one aspect, the invention provides compositions and methods that are useful in treating or preventing endocrine FGF-related diseases or disorders. | 2020-04-30 |
20200131258 | SCFV-FC DIMERS THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY - An scFv-Fc dimer binds and neutralizes TGFβ1 selectively and with high affinity and avidity. The scFv region may comprise the same VH and VL domains or CDR regions as metelimumab. The unique combination of their smaller size, high selectivity, potency against TGFβ1, and long in vivo half-life makes the scFv-Fc dimers ideal candidates for therapeutic applications. | 2020-04-30 |
20200131259 | COMPOSITIONS AND METHODS FOR GROWTH FACTOR MODULATION - Provided herein are proteins, antibodies, assays and methods useful for modulating growth factor levels and/or activities. In some embodiments, such growth factors are members of the TGF-β superfamily of proteins. | 2020-04-30 |
20200131260 | Novel Angiopoietin 2, VEGF Dual Antagonists - The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis. | 2020-04-30 |
20200131261 | BINDING MOLECULE SPECIFIC FOR LRIG-1 PROTEIN AND USE THEREOF - The present invention relates to a binding molecule capable of specifically binding to Lrig-1 protein, which is located on the surface of a regulatory T cell. The binding molecule provided in the present invention can activate the function of regulatory T cells to effectively prevent, ameliorate, or treat diseases caused by excessive activation or expression of various immune cells and inflammatory cells, for example, immune-related diseases such as autoimmune disease, graft-versus-host disease, organ transplant rejection, asthma, atopy, acute or chronic inflammatory disease, etc. In addition, the binding molecule, preferably the antibody, specific for the Lrig-1 protein according to the present invention has advantages of more effectively targeting the Lrig-1 protein as compared with antibodies against Lrig-1 which are previously commercially available, and also possessing very good binding capacity thereto. | 2020-04-30 |
20200131262 | TARGETING MODULES FOR UNIVERSAL CHIMERIC ANTIGEN RECEPTOR EXPRESSING IMMUNE CELLS AND USE IN THE TREATMENT OF CANCER INFECTIONS AND AUTOIMMUNE DISORDERS - The present invention relates to a targeting module comprising a chemically synthesized peptide binding moiety specific for a human cell surface protein or protein complex, a kit comprising the targeting module and a vector or a cell comprising a nucleic acid encoding a universal chimeric antigen receptor and the use for the treatment of cancer, infections and autoimmune disorders. | 2020-04-30 |
20200131263 | ANTI-GITR ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND PHARMACEUTICAL USE THEREOF - Provided are an anti-GITR antibody, an antigen-binding fragment thereof, and pharmaceutical uses thereof. Further provided are a chimeric antibody and a humanized antibody containing a CDR of the anti-GITR antibody, a pharmaceutical composition containing the anti-GITR antibody or the antigen-binding fragment thereof, and use of the anti-GITR antibody in preparation of an anti-cancer drug. In particular, provided is a humanized anti-GITR antibody, and its use in the preparation of drugs for treating GITR-mediated diseases or disorders. | 2020-04-30 |
20200131264 | Anti-TREM1 Antibodies and Methods of Use Thereof - The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM1 protein, e.g., a mammalian TREM1 or human TREM1, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof. | 2020-04-30 |
20200131265 | FcgammaRIIB-Specific Antibodies and Methods of Use Thereof - The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention. | 2020-04-30 |
20200131266 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT IMMUNOSPECIFICALLY BIND TO BTN1A1 - Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Also included are molecules having an antigen binding fragment that immunospecifically bind to BTN1A1 dimers, such as anti-BTN1A1 dimer antibodies. Also provided are methods for treating anti-PD-1 therapy or anti-PD-L1 therapy resistant or refractory cancers. | 2020-04-30 |
20200131267 | ANTIBODIES - The present invention relates to antibodies specific for one or more antigens, bispecific antibodies containing one or more domains with specificity to the target(s), and to immunocytokines. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines. | 2020-04-30 |
20200131268 | NKp46 BINDING PROTEINS - Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease. | 2020-04-30 |
20200131269 | METHODS OF TREATING CANCER USING ANTIBODIES AND MOLECULES THAT BIND TO BTN1A1 OR BTN1A1-LIGANDS - Provided herein are methods for treating cancer using molecules having an antigen binding fragment that immunospecifically binds to BTN1A1 or a BTN1A1 ligand, such as anti-BTN1A1 antibodies or anti-BTN1A1 ligand antibodies. Also provided herein are BTN1A1 ligands, such as Galectin-1, Galectin-9, Neuropilin-2, and B- and T-Lymphocyte Attenuator. | 2020-04-30 |
20200131270 | COMBINATION USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR - The present invention provides a novel therapeutic strategy using an inhibitor targeting PD-1/PD-L1. A pharmaceutical composition which comprises a COX-2 inhibitor and is administered before, after or simultaneously with the administration of an inhibitor targeting PD-1/PD-L1. A potentiator for the immunostimulatory effect of an inhibitor targeting PD-1/PD-L1, which comprises a COX-2 inhibitor. | 2020-04-30 |
20200131271 | ANTIBODIES TO OPGL - Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described. | 2020-04-30 |
20200131272 | ANTI-CD27 ANTIBODIES - The present invention relates to anti-CD27 antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease. | 2020-04-30 |
20200131273 | CHIMERIC CANINE ANTI-CD20 ANTIBODY - The disclosure relates to caninized chimeric anti-CD20 antibodies to the canine protein CD20 and methods of use to treat certain disorders such as non-Hodgkins B-cell lymphoma in dogs. | 2020-04-30 |
20200131274 | Therapeutic molecules binding PSMA - The invention relates to improved binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer. | 2020-04-30 |
20200131275 | MULTISPECIFIC ANTIBODY CONSTRUCTS BINDING TO MUC1 AND CD3 - The present invention pertains to multispecific antibody constructs directed against the cancer antigen MUC1 and the T cells antigen CD3. In particular, the multispecific antibody constructs recruit T cells to the cancer site. The design of the multispecific antibody constructs show strong antigen binding and high T cell activation. | 2020-04-30 |
20200131276 | METHODS OF TREATING CANCERS USING PD-1 AXIS BINDING ANTAGONISTS AND TAXANES - The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane. | 2020-04-30 |
20200131277 | Engineered Antibodies for the Detection of Phosphorylated Tyrosine - Presented herein are novel phosphotyrosine binding compositions, including antibodies and antibody fragments. The inventors of the present disclosure have resolved the crystal structures of two widely utilized pan-specific pY antibodies, PY20 and 4G10. These two known antibodies, although developed independently from animal immunizations, have surprisingly similar modes of recognition of the phosphate group, and revealed a generic binding structure among pan-specific pY antibodies. Based on this newly discovered convergent structure, engineered CDR-L3 loops were developed that impart greatly improved affinity to pY binding antibodies and other pY binding compositions. The inventions disclosed herein include antibodies and antibody fragments bearing these novel CDR-L3 sequences and methods of using such pY binding compositions for the detection of phosphotyrosine-bearing proteins. | 2020-04-30 |
20200131278 | ANTI-ACETAMINOPHEN ANTIBODIES AND ACETAMINOPHEN PROTEIN ADDUCTS - The present disclosure provides isolated antibodies that bind to acetaminophen-protein adducts that are useful in the detection and diagnosis of acetaminophen-induced toxicity. | 2020-04-30 |
20200131279 | THICKENER, COMPOSITION, AND SHEET - It is an object of the present invention to provide a thickener capable of exhibiting excellent light resistance. The present invention relates to a thickener comprising cellulose fibers having a fiber width of 8 nm or less and water, wherein the thickener is a slurry or a gel, and when the thickener is filled in a colorless and transparent glass cell having an inside dimension of 1 cm in depth×4 cm in width×4.5 cm in height and the thickener is then irradiated with ultraviolet rays with a wavelength of 300 nm or more and 400 nm or less, using a xenon lamp, from the side of the maximum area surface of the glass cell, so as to be an irradiance of 180 W/m | 2020-04-30 |
20200131280 | PROCESS FOR RECOVERING AN ESTERIFIED CELLULOSE ETHER FROM A REACTION PRODUCT MIXTURE - A process for recovering an esterified cellulose ether from a reaction product mixture obtained from a reaction of (a) a cellulose ether with (b) an aliphatic monocarboxylic acid anhydride or a di- or tricarboxylic acid anhydride or a combination of an aliphatic monocarboxylic acid anhydride and a di- or tricarboxylic acid anhydride, comprises the steps of (i) contacting the reaction product mixture with an aqueous liquid and precipitating the esterified cellulose ether from the reaction product mixture, and (ii) isolating the precipitated esterified cellulose ether from the mixture obtained in step (i). Tackiness of the esterified cellulose ether can be reduced when a cellulose ether is added before or in step (i) to the reaction product mixture, to the aqueous liquid or a combination thereof. | 2020-04-30 |
20200131281 | ALPHA-1,3-GLUCAN GRAFT COPOLYMERS - Compositions are disclosed herein comprising a graft copolymer that comprises: (i) a backbone comprising an alpha-1,3-glucan ether or ester compound, and (ii) one or more alpha-1,3-glucan side chains comprising at least about 50% alpha-1,3 glycosidic linkages. Further disclosed are reactions for producing such graft copolymers, as well as their use in various applications. | 2020-04-30 |
20200131282 | POLYMERIZATION AND ISOLATION OF LOW VISCOSITY POLYMERS USING PASTILLATION TECHNOLOGY - A process to form an olefin-based polymer, said process comprising at least the following steps: a) polymerizing a reaction mixture comprising an olefin, in at least one reactor, in a solution polymerization, to form a polymer solution; b) feeding at least a portion of the polymer solution through at least one devolatilizer, to form the olefin-based polymer, in melt form; c) feeding at least a portion of the olefin-based polymer, in melt, form through a heat exchanger, and then into a pastillation apparatus to form polymer particles. | 2020-04-30 |
20200131283 | CATALYST SYSTEM FOR MULTI-BLOCK COPOLYMER FORMATION - The present disclosure relates to a catalyst system for use in forming a multi-block copolymer, said copolymer containing therein two or more segments or blocks differing in chemical or physical properties, a polymerization process using the same, and the resulting polymers, wherein the composition comprises the admixture or reaction product resulting from combining: (A) a first olefin polymerization procatalyst, (B) a second olefin polymerization procatalyst capable of preparing polymers differing in chemical or physical properties from the polymer prepared by procatalyst (A) under equivalent polymerization conditions, (C) an activator, and (D) a chain shuttling agent. | 2020-04-30 |
20200131284 | PROCESS FOR THE PREPARING HETEROPHASIC PROPYLENE COPOLYMERS - Process for producing a heterophasic propylene copolymer using a specific class of metallocene complexes in a multistage polymerization process including a gas phase polymerization step. The invention further relates to the use of catalysts which comprise a specific class of metallocene complexes to produce a heterophasic propylene copolymer in a multistep process including a gas phase polymerization step. | 2020-04-30 |
20200131285 | NOVEL POLYMERS AND DNA COPOLYMER COATINGS - Some embodiments described herein relate to new polymer coatings for surface functionalization and new processes for grafting pre-grafted DNA-copolymers to surface(s) of substrates for use in DNA sequencing and other diagnostic applications. | 2020-04-30 |
20200131286 | PREPOLYMER, METHOD OF PREPARING THE SAME, RESIN COMPOSITION AND ARTICLE MADE THEREFROM - A prepolymer, which is prepared by subjecting an unsaturated bond-containing compound and a bis(vinylphenyl) compound monomer or a polymer thereof to a prepolymerization reaction, is provided. The bis(vinylphenyl) compound contains between 80% and 99% of para-para vinyl groups and has a monomer content of between 80% and 100%. Moreover, a resin composition comprising the prepolymer and an additive, a method of preparing the prepolymer, and an article made from the resin composition are also provided. | 2020-04-30 |
20200131287 | POLYMER PARTICLES - Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents. | 2020-04-30 |
20200131288 | CONTINUOUS SYNTHESIS OF AN ETHYLENE AND BUTADIENE COPOLYMER - A process for the synthesis of an ethylene/butadiene copolymer is provided. The process is continuous and comprises: | 2020-04-30 |
20200131289 | BIARYL PHENOXY GROUP IV TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION - Embodiments are directed to catalyst systems comprising at least one metal ligand complex and to processes for polyolefin polymerization incorporating the catalyst systems. The metal ligand complexes have the following structures: | 2020-04-30 |
20200131290 | Preparation Method for Fluorine- and Chlorine-Containing Conductive Polymer Resin and Single- or Double-Sided Filled Composite Thin Film Prepared Using Same and the Preparation Method Therefor - Disclosed are a method for a preparing fluorine- and chlorine-containing conductive polymer resin, a single-side or double-side filled composite film prepared using the fluorine- and chlorine-containing conductive polymer resin, and a method for preparing the film. The fluorine- and chlorine-containing conductive polymer single-side or double-side filled composite film comprises a microporous film skeleton and the fluorine- and a chlorine-containing conductive polymer resin. The composite film is mechanically stronger, more waterproof, more impervious to water and toxic and harmful chemicals, and more moisture permeability. When applied to biochemical protective clothing, it can greatly enhance the combat effectiveness of the soldiers because it is light and more impervious to water and toxic and harmful chemicals, brings about comfort, and keeps the soldiers warm. When applied to fuel cells, it can provide better electrical properties due to its high conductivity and can allow the fuel, such as hydrogen or alcohol, to burn more completely. | 2020-04-30 |
20200131291 | THREE-DIMENSIONAL MODELING COMPOSITION SET AND THREE-DIMENSIONAL MODELING METHOD - A three-dimensional modeling composition set includes a model material and a support material. The model material contains a heterocyclic acrylate having oxygen as a heteroatom in the molecule and a first photopolymerization initiator. The support material contains a water-soluble polymerizable compound and a second photopolymerization initiator. The heterocyclic acrylate may be an acrylate having one of a dioxane ring structure and a dioxolane ring structure. | 2020-04-30 |
20200131292 | PROCESS FOR PREPARING A STATISTICAL COPOLYMER BASED ON ACYCLIC DIENE MONOMERS AND CYCLIC DIENE MONOMERS, COPOLYMERS AND COMPOSITIONS CONTAINING SAME - A process for preparing a random copolymer based on at least one acyclic diene monomers and on at least one cyclic diene monomer is provided. The process comprises a step of copolymerization, in the presence of a polar agent and an anionic initiator in a polymerization solvent, of at least one acyclic diene monomer and of at least one cyclic diene monomer of which one C═C double bond is endocyclic and conjugated to an exocyclic C═C double bond, at a polymerization temperature below | 2020-04-30 |
20200131293 | NITRILE GROUP-CONTAINING COPOLYMER RUBBER - A nitrile group-containing copolymer rubber including 10 to 60 wt % of an α,β-ethylenically unsaturated nitrile monomer unit and 1 to 60 wt % of an α,β-ethylenically unsaturated dicarboxylic acid monoester monomer unit, and having an iodine value of 120 or less, wherein a processability index Ipro (Ipro=CC×SA) is 0.0030 or less, where the processability index Ipro is the product of the carboxyl group content CC, which is the number of moles of carboxyl groups per 100 g of nitrile group-containing copolymer rubber, and the absorbance area SA of a carboxylic anhydride group determined by infrared spectroscopy. | 2020-04-30 |
20200131294 | HIGH-STRENGTH LOW-CREEP THERMOPLASTIC ELASTOMER - A polystyrene-g-(polyisobutylene-b-polystyrene) is taught. The polystyrene-g-(polyisobutylene-b-polystyrene) is synthesized by first providing a polystyrene backbone. Once the polystyrene backbone is provided, the polystyrene backbone is acetylated to provide acetyl groups on the polystyrene backbone. Next, the acetyl groups are converted to —C(CH | 2020-04-30 |
20200131295 | METHOD FOR MANUFACTURING RUBBER-REINFORCED STYRENIC RESIN POWDER AND RUBBER-REINFORCED STYRENIC RESIN POWDER - A method for manufacturing a rubber-reinforced styrenic resin powder comprising 40% by mass or more of a rubbery polymer, satisfying the following conditions (1) to (4): | 2020-04-30 |
20200131296 | Block Copolymer - The present application can provide a block copolymer and a use thereof. The block copolymer of the present application can have excellent self-assembly properties or phase separation characteristics and excellent etching selectivity, and various other functions as required can be freely imparted thereto. | 2020-04-30 |
20200131297 | SHEET MOLDING COMPOUND, FIBER-REINFORCED COMPOSITE MATERIAL, AND METHOD FOR PRODUCING FIBER-REINFORCED COMPOSITE MATERIAL - A sheet molding compound according to a first aspect of the present invention comprises:
| 2020-04-30 |
20200131298 | COMPOSITION FOR POLYURETHANE FOAM PRODUCTION, POLYURETHANE FOAM, AND SOUND-ABSORBING MEMBER - The purpose of the present invention is to provide: a composition for polyurethane foam production which gives polyurethane foam having a low density and excellent sound-absorbing properties; polyurethane foam obtained from the composition; and a sound-absorbing member. The composition for polyurethane foam production of the present invention is characterized by comprising a polyol, a polyisocyanate, a catalyst, a blowing agent, a foam stabilizer, and an auxiliary blowing agent, the blowing agent being water, the amount of which is 4-11 parts by mass per 100 parts by mass of the polyol, and the auxiliary blowing agent being a liquid halogenated olefin, the amount of which is 10-30 parts by mass per 100 parts by mass of the polyol. | 2020-04-30 |
20200131299 | SHAPE MEMORY POLYMERS - New shape memory polymer compositions, methods for synthesizing new shape memory polymers, and apparatus comprising an actuator and a shape memory polymer wherein the shape memory polymer comprises at least a portion of the actuator. A shape memory polymer comprising a polymer composition which physically forms a network structure wherein the polymer composition has shape-memory behavior and can be formed into a permanent primary shape, re-formed into a stable secondary shape, and controllably actuated to recover the permanent primary shape. Polymers have optimal aliphatic network structures due to minimization of dangling chains by using monomers that are symmetrical and that have matching amine and hydroxl groups providing polymers and polymer foams with clarity, tight (narrow temperature range) single transitions, and high shape recovery and recovery force that are especially useful for implanting in the human body. | 2020-04-30 |
20200131300 | SULFOBETAINE GROUP-CONTAINING REACTIVE COMPOUND, POLYMER THEREOF, AND METHOD FOR PRODUCING POLYMER - A polymer comprising at least 1% by mole of a structural unit represented by Formula (2). In Formula (2), two R | 2020-04-30 |
20200131301 | SHELF-STABLE RIGID FOAM FORMULATIONS - The shelf life of B-side compositions comprising a polyol, a surfactant, a blowing agent, an organometallic or metal salt catalyst wherein the metal of the catalyst comprises Zn or Bi, and from 1 to 10 weight percent water is improved by the addition of a thiol compound. | 2020-04-30 |
20200131302 | SILICONE-POLYETHER COPOLYMER, ISOCYANATE-FUNCTIONAL SILICONE-POLYETHER COPOLYMER FORMED THEREWITH, SILICONE-POLYETHER-URETHANE COPOLYMER, SEALANTS COMPRISING SAME, AND RELATED METHODS - A silicone-polyether copolymer has the formula X—Y, where X is a silicone moiety having a particular structure and Y is a polyether moiety. An isocyanate-functional silicone-polyether copolymer formed therewith is also disclosed. Further, a silicone-poly-ether-urethane copolymer formed with the isocyanate-functional silicone-polyether copolymer is disclosed. Related methods of preparation as well as sealants and cured products thereof are further disclosed. | 2020-04-30 |
20200131303 | ARAMID-BASED EPOXY RESIN AND PREPARATION METHOD THEREOF - The present invention discloses an aramid-based epoxy resin and a method of making same, including the steps of reacting aramid fiber powder as a raw material with a metallization reagent; grafting a plurality of ethylene oxide, propylene oxide or a mixture thereof to an activated amide group of the aramid to introduce a reactive functional group hydroxyl; and then conducting a ring-opening and closing reaction by using epichlorohydrin to obtain a liquid aramid-based epoxy resin. | 2020-04-30 |
20200131304 | MULTICOLORED ELECTROCHROMIC POLYMER COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME - This disclosure relates generally to electrochromic polymers that include a plurality of π-conjugated chromophores in spaced relation with one another, and a plurality of conjugation-break spacers (CBSs), where at least one CBS separates adjacent chromophores. The chromophores may be colored in the neutral state, and multicolored to transmissive in different oxidization states. | 2020-04-30 |
20200131305 | ELASTOMER - An elastomer is provided, which is a product of reacting C | 2020-04-30 |
20200131306 | SPHERICAL POLYESTER RESIN PARTICLES AND METHOD FOR PRODUCING SAME - Spherical polyester-based resin particles characterized in that the spherical polyester-based resin particles contain a polyester-based resin and have a crystallinity of 20% or less and an average circularity of 0.96 or more. The spherical polyester-based resin particles according to the present invention can provide suitable resin particles as compounding agents for cosmetics such as foundation, antiperspirants, and skin scrubs; various agents such as matte coating agents for paints, rheology modifying agents, antiblocking agents, slipperiness-imparting agents, light diffusion agents, electroconductive agents, and diagnostic testing agents for medical use; and additives to molded articles such as automobile materials and construction materials. | 2020-04-30 |
20200131307 | Multilayer Container And Method For Producing Regenerated Polyester - An object of the present invention is to provide a multilayer container in which yellowing of a regenerated polyester at the time of recycle is suppressed. Furthermore, another object of the present invention is to provide a method for producing a regenerated polyester from the aforementioned multilayer container. The multilayer container of the present invention includes a polyester resin composition layer containing a polyester resin (X) and an antioxidant; and a polyamide resin composition layer containing a polyamide resin (Y) and a cobalt salt, wherein the polyamide resin (Y) has a structural unit derived from a diamine and a structural unit derived from a dicarboxylic acid; 50 mol % or more of the structural unit derived from a diamine is a structural unit derived from xylylenediamine; the content of the antioxidant in the polyester resin composition layer is 0.01 to 1% by mass; and the content of the cobalt salt in the polyamide resin composition layer is 100 to 1,000 ppm as expressed in terms of cobalt. | 2020-04-30 |
20200131308 | POLYESTER MIXTURE AND MANUFACTURING METHOD FOR POLYESTER - A method for manufacturing polyester comprises mixing Bis(2-Hydroxyethyl) terephthalate monomer with terephthalic acid to form a mixture, in which the Bis(2-Hydroxyethyl) terephthalate monomer is represented by formula (I) below: | 2020-04-30 |
20200131309 | PHASE DIFFERENCE FILM - An object of the present invention is to provide a phase difference film that can exhibit sufficient reciprocal wavelength dispersibility. The present invention includes a copolymer containing at least one selected from a unit represented by Formula (1) and a unit represented by Formula (2), and a unit represented by Formula (3), in which 20 nm2020-04-30 | |
20200131310 | ORGANIC FLUORINE COMPOUND, LUBRICANT, AND PROCESSING METHOD OF MAGNETIC RECORDING MEDIUM - According to one aspect of the present invention, an organic fluorine compound is represented by a general formula | 2020-04-30 |
20200131311 | METHOD OF MAKING A POLY(PHENYLENE ETHER) AND POLY(PHENYLENE ETHER) PREPARED THEREBY - A method of making a poly(phenylene ether) includes oxidatively polymerizing a combination of a phenolic monomer and a monofunctional phenylene ether oligomer in the presence of an organic solvent and a copper-amine catalyst. The method further includes terminating the oxidative polymerization to form a post-termination reaction mixture; combining an aqueous solution comprising a chelant with the post-termination reaction mixture to form a chelation mixture including an aqueous phase having chelated copper ion, and an organic phase having dissolved poly(phenylene ether); separating the aqueous phase and the organic phase; and isolating the poly(phenylene ether) from the organic phase. | 2020-04-30 |
20200131312 | CLEAR POLYAMIDE RESINS, ARTICLES, AND METHODS - Polyamide resins including the reaction product of an intimate mixture of at least two monomers selected from HMDA and a diamine; and an organic diacid, wherein sebacic acid is present in the organic diacid in an amount of less than or equal to about 50 mol. %, and associated articles and methods are provided herein. | 2020-04-30 |
20200131313 | TRANSPARENT POLYIMIDE FILM - A transparent polyimide film, prepared from a copolymerized polyamide acid according to a chemical cyclization method, is provided. The copolymerized polyamide acid requires at least a semi-aromatic polyamide acid, and the semi-aromatic polyamide acid is formed by reacting cyclobutane-1,2,3,4-tetracarboxylic dianhydride (CBDA) and 2,2′-bis(trifluoromethyl)diaminodiphenyl (TFMB). The molar number of dianhydrides of the semi-aromatic polyamide acid is more than 20% of the total molar number of anhydrides of the copolymerized polyamide acid, so that the transparent polyimide film has a light transmittance greater than 80%, a chroma b* less than 5, and a CTE less than 35 ppm/° C. | 2020-04-30 |
20200131314 | RESIN COMPOSITION, LAMINATE AND MANUFACTURING METHOD THEREOF, ELECTRODE, SECONDARY BATTERY, AND ELECTRIC DOUBLE LAYER CAPACITOR - An object of the present invention is to provide a resin composition containing: (a) a resin containing at least one of a polyimide, a polyamideimide, and a polybenzoxazole, having at least one acidic functional group among a phenolic hydroxyl group, a carboxyl group, and a sulfonic acid group in a side chain, and having an acidic functional group concentration of 3.4 mol/kg or more; and (b) a basic compound. The resin composition has high long-term stability in the form of an aqueous solution while having high strength and high modulus, has good dispersibility of a filler, and has a good binding property as a binder. | 2020-04-30 |
20200131315 | POLYAMIDE-IMIDE RESIN FILM - The present invention relates to a polyamide-imide resin film having a low birefringence index, including: a polyamide-imide block copolymer containing an amide repeating unit to which an isophthaloyl group and an aromatic diamine residue are bonded; an imide repeating unit; and a trivalent functional group containing an aromatic tricarbonyl group. | 2020-04-30 |
20200131316 | (METH)ACRYLOYL GROUP-CONTAINING ORGANOSILOXANE - One of the purposes of the present invention is to provide a (meth)acryloyl group-containing organosiloxane which provides a strong cured product showing excellent adhesion to a substrate. The present invention provides a (meth)acryloyl group-containing organosiloxane represented by the following formula (1): | 2020-04-30 |
20200131317 | SOLVENT-FREE PHASE-INVERSION EMULSIFICATION PROCESS FOR PRODUCING AMORPHOUS POLYESTER RESIN EMULSIONS - An organic solvent-free phase-inversion emulsification process for a low molecular weight amorphous polyester resin includes forming a mixture by adding to the amorphous polyester resin: i. a surfactant; ii. an aqueous solution of a neutralizing agent; and iii. a portion of water that is about 40% or less of a total amount of water used to form a phase-inversion emulsion, heating the mixture to dissolve the amorphous polyester resin to provide a dissolved amorphous polyester and adding water up to the total amount of water to the dissolved amorphous polyester to form a latex of the amorphous polyester resin. The resultant latex is used in processes of making a toner composition. A latex of an amorphous polyester resins is made by such processes have latex particles that are unimodal. | 2020-04-30 |
20200131318 | LIGNIN PELLETS AND PROCESS FOR PRODUCING SAME - Lignin pellets comprising fused lignin are described herein. The lignin pellets may further comprise a processing aid, and/or a surfactant, and/or a chemical modifying agent, and/or a compatibilizer and/or a thermoplastic polymer. An extrusion process for producing the lignin pellets and their use in the manufacture of lignin thermoplastic blend products, polyols, polyphenols, polyaromatics and polyurethanes is also disclosed herein. The extruded lignin pellet may be dry-blended with additional thermoplastic and/or additive and then directly processed using processes such as injection molding, compression molding, extrusion, extrusion coating, blowing, thermoforming, stamping, foaming, fiber drawing, calendering or rolling. | 2020-04-30 |
20200131319 | Method of manufacturing high temperature resistant composite materials - Methods of manufacturing high-temperature composite materials using carbon nanotube to improve the efficiency of insulation applied to propulsion systems for aerospace equipment including 5 steps: step 1: Select necessary materials and equipment, step 2: disperse MW-CNTs in the polar solution, step 3: distribute MW-CNTs evenly in the resin, step 4: eliminate residual solvents, step 5: curing phenolic resin composites. | 2020-04-30 |
20200131320 | POLYMER MEMBRANE AND METHODS OF MANUFACTURING THEREOF - This invention relates to a polymer membrane comprising a hydrogen bond donor polymer and a hydrogen bond acceptor polymer and to the use of such membrane as the shell of a capsule. The invention also relates to a method of manufacturing a polymer membrane comprising a step of contacting an aqueous phase comprising a first polymer, and an oil phase comprising a second different polymer; wherein one polymer is a hydrogen bond donor polymer and the other polymer is a hydrogen bond acceptor polymer. The invention also relates to a method of encapsulation comprising a step of manufacturing a polymer membrane. | 2020-04-30 |
20200131321 | PROCESS FOR PREPARING A BIAXIALLY ORIENTED MULTILAYERED FILM - The invention relates to a process for preparing a biaxially oriented multilayered film, the film comprising at least one layer comprising a polyolefin composition and at least one layer comprising a polyamide composition, the process comprising the steps of: a) Melting a polyamide composition comprising: i. a semi-crystalline polyamide Y comprising: ⋅monomeric units derived from caprolactam in an amount of at least 75 wt %; ⋅monomeric units derived from an aliphatic diamine in an amount of between 2.5 and 12.5 wt %; ⋅monomeric units derived from an aromatic diacid in an amount of between 2.5 and 12.5 wt %; wherein the weight percentage is given with respect to the total weight of the polyamide Y; ii. an amorphous polyamide in an amount of between 2.5 and 50 wt % with respect to the total weight of the polyamide composition; wherein the amorphous polyamide comprises: ⋅monomeric units derived from an aliphatic diamine X in an amount of between 30 and 70 wt %; ⋅monomeric units derived from an aromatic diacid in an amount of between 30 and 70 wt %; wherein the weight percentage is given with respect to the total weight of the amorphous polyamide; b) Melting a composition comprising a polyolefin; c) Co-extruding at least the melts obtained from a) and b) to form a film of at least two layers; d) Cooling the film to a temperature of at most 50° C., while the film is transported in a direction, referred to as machine direction; e) Stretching the film obtained in step d) with a stretch ratio of at least 13, at a temperature between the Tg of polyamide Y and Tm of the polyolefin, wherein the stretch ratio is defined as being the product of the stretch ratio parallel to the machine direction and the stretch ratio perpendicular to the machine direction. The invention also relates to a biaxially oriented multilayered film obtainable by the process. | 2020-04-30 |
20200131322 | FILM, METHOD FOR EVALUATING OPTICAL HOMOGENEITY OF FILM, AND FILM PRODUCTION METHOD - A film having excellent optical homogeneity, which is suitably used as an optical film in an image display device, and a method for manufacturing the same. Moreover, an evaluation method which can evaluate the optical homogeneity of the film with a higher precision than in conventional evaluation methods is provided. A film that is a cast film containing a resin having a weight average molecular weight of 200,000 or more, wherein, when line profiles in a direction h and a direction v which are orthogonal to each other in a film inverse space image obtained by Fourier transforming a projection image obtained by a projection method using the cast film are a line profile h and a line profile v. | 2020-04-30 |
20200131323 | SHEETLIKE SEMIFINISHED PRODUCT HAVING A PLASTIC MATRIX - A sheetlike semifinished product comprising a matrix having at least one latent reactive plastics composition which is curable to afford an elastomer, in particular a thermoplastic elastomer, and fibers embedded in the matrix. A process for producing sheetlike semifinished products is further disclosed. | 2020-04-30 |
20200131324 | THERMOSETTING RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIAL, PREFORM, FIBER-REINFORCED COMPOSITE MATERIAL, AND METHOD OF PRODUCING FIBER-REINFORCED COMPOSITE MATERIAL - A thermosetting resin composition for a fiber-reinforced composite material includes a domain of a base resin [A]; and a domain of a curing agent [B] and/or a domain of a catalyst [C], the thermosetting resin composition having a specific gravity of 0.90 to 1.30, and a complex viscosity η* determined by dynamic viscoelasticity measurement at 25° C. of 1×10 | 2020-04-30 |
20200131325 | UNIDIRECTIONALLY-ORIENTED TAPE-SHAPED PREPREG, AND MOLDED ARTICLE THEREOF - A tape-shaped prepreg includes unidirectionally-oriented reinforcing fibers, and a thermoplastic resin, which prepreg has a good and uniform tape thickness and tensile strength, and which allows for producing a final product at a low cost. The tape-shaped prepreg includes unidirectionally-oriented reinforcing fibers and a thermoplastic resin composition, and has an average thickness of 0.2 mm or more and 1.5 mm or less, a void content of 5% by volume or less, and a degree of dispersity of reinforcing fibers of 0.5 or less. | 2020-04-30 |
20200131326 | SYSTEMS, DEVICES, AND METHODS FOR PROMOTING IN SITU POLYMERIZATION WITHIN NANOMATERIAL ASSEMBLIES - The present disclosure is directed to synthesizing a nanomaterial-polymer composite via in situ interfacial polymerization. A nanomaterial is exposed to a solution having a first solute dissolved in an aqueous solvent to uniformly, or substantially uniformly, distribute the solvent throughout the porosity of the network of the nanomaterial. The nanomaterial is then exposed to a second solution having a second solute dissolved in an organic solvent, which is substantially immiscible with the first solvent, with the first solute reacting with the second solute. The first and second solutions can be stirred, or otherwise moved with respect to each other, to facilitate transport of the second solution throughout the nanomaterial to promote reaction of the polymer within the nanomaterial to produce a polymer composite having uniform morphology. | 2020-04-30 |
20200131327 | VISCOELASTIC FLEXIBLE FOAMS COMPRISING HYDROXYL-TERMINATED PREPOLYMERS - This invention relates to a process for preparing viscoelastic flexible polyurethane foam comprising reacting an isocyanate component with an isocyanate-reactive component that comprises a polyol blend having a hydroxyl number of 56 to 250 and an average functionality of greater than 2, and a hydroxyl-terminated prepolymer. The invention also relates to viscoelastic flexible polyurethane foams. | 2020-04-30 |
20200131328 | THERMOCHROMIC FENESTRATION FILMS CONTAINING VANADIUM DIOXIDE NANOCRYSTALS - Vanadium oxide nanomaterial composite compositions and substrates including films comprising vanadium oxide nanomaterial composite compositions are described. A film and composition generally including a polymeric matrix; and a crystalline vanadium oxide nanomaterial dispersed in the polymeric matrix, wherein the crystalline vanadium oxide nanomaterial comprises a smallest dimension between about 100 nm and about 5 nm. | 2020-04-30 |
20200131329 | MAGNESIUM CARBONATE - Provided is a novel magnesium carbonate. The magnesium carbonate has a zeta potential of 5 mV or more and a BET specific surface area of 25 m | 2020-04-30 |
20200131330 | REINFORCING MATERIAL FOR RUBBER COMPRISING ALUMINOSILICATE PARTICLES AND RUBBER COMPOSITION FOR TIRES COMPRISING THE SAME - The present disclosure relates to a reinforcing material for rubber including aluminosilicate particles and a rubber composition for tires including the same. The reinforcing material for rubber according to the present disclosure exhibits excellent dispersibility in the rubber composition and reinforcing effect, and thus can be suitably used for eco-friendly tires requiring high efficiency and high fuel efficiency characteristics. | 2020-04-30 |